Digital Health Program for Colorectal Cancer Screening
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new digital program called mPATH-CRC, designed to help people screen for colorectal cancer from home. Participants use an app on their devices to learn about screening options and request tests. The trial aims to evaluate the program's effectiveness in various healthcare settings. It suits individuals aged 45-74 who haven't had recent colorectal cancer screenings and have a phone number on file. As an unphased trial, it provides a unique opportunity to contribute to innovative research that could simplify cancer screening for many.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this digital health program is safe for colorectal cancer screening?
Research has shown that mPATH-CRC, a digital health program for colorectal cancer screening, has been used in earlier studies without safety concerns. The program educates users about their screening options and allows them to request tests if needed. As a digital tool rather than a drug or medical procedure, mPATH-CRC poses minimal risk of physical harm. Participants use the program on their own devices, further reducing potential safety issues. Previous studies have examined its effectiveness and usability, suggesting that users generally have a positive experience.12345
Why are researchers excited about this trial?
Researchers are excited about the mPATH-CRC program because it introduces a digital twist to colorectal cancer screening. Unlike traditional methods that rely on in-person consultations and procedural reminders, mPATH-CRC uses a WebApp accessible via a simple text message invitation. This app not only verifies when you're due for a screening but also educates you about your options and allows you to request a screening test from the comfort of your home. This convenient and streamlined approach aims to increase screening rates by making the process more accessible and user-friendly.
What evidence suggests that the mPATH-CRC program is effective for colorectal cancer screening?
In this trial, participants assigned to the mPATH-CRC arm will receive a text message inviting them to use the mPATH-CRC WebApp. Studies have shown that mPATH-CRC effectively increases colorectal cancer screening rates. Earlier research found the tablet version of mPATH-CRC easy for patients to use and successful in encouraging them to complete their screenings. The program educates users about screening options and allows them to request a test directly, simplifying and enhancing accessibility. However, another study found that once tests were ordered, completion rates were similar whether participants used mPATH or standard care. This suggests that while mPATH-CRC helps initiate the process and order tests, completion rates may not differ significantly from usual care. Overall, mPATH-CRC aims to simplify the screening process and encourage more people to get tested.12467
Are You a Good Fit for This Trial?
This trial is for individuals who are eligible for colorectal cancer screening. Participants will use their own devices to access a cloud-based digital health program, mPATH-CRC, aimed at facilitating the screening process. The specific inclusion and exclusion criteria details were not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Digital Health Navigation
Participants use the mPATH-CRC WebApp to verify if they are due for CRC screening, learn about options, and request a screening test
Follow-up
Participants are monitored for completion of CRC screening tests and outcomes
What Are the Treatments Tested in This Trial?
Interventions
- mPATH-CRC
Find a Clinic Near You
Who Is Running the Clinical Trial?
Digital Health Navigation Solutions, Inc
Lead Sponsor
Wake Forest University Health Sciences
Collaborator
National Cancer Institute (NCI)
Collaborator